» Articles » PMID: 31287000

Position Statement on Access to Care in Rare Liver Diseases: Advancements of the European Reference Network (ERN) RARE-LIVER

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2019 Jul 10
PMID 31287000
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The European Reference Network for rare liver diseases (ERN RARE-LIVER) is a Europe-wide network of paediatric and adult hepatologists from expert centres in close collaboration with patient advocates from the various disease-areas covered in our ERN. The ERN is focused on providing more equitable care across Europe and creates a network of both medical specialists and patient experts in rare liver disease. This position paper summarizes the achievements of the first year and plots the route for the near future for ERN RARE-LIVER, as discussed during a strategy meeting that took place 27 and 28 February 2018 in Nijmegen, the Netherlands. ERN RARE-LIVER has established itself as a group with experts, hospitals and patients. One of the tools to improve communication is the clinical patient management system (CPMS) that allows access to expert consultation by European physicians confronted with a patient with rare liver disease. ERN RARE-LIVER will function as the platform to improve healthcare by initiating registries, foster research efforts and coordinate development of clinical guidelines in Europe.

Citing Articles

Outcome of Children with Transjugular Intrahepatic Portosystemic Shunt: A Meta-Analysis of Individual Patient Data.

Deniz S, Schinner R, Monroe E, Horslen S, Srinivasa R, Lv Y Cardiovasc Intervent Radiol. 2023; 46(9):1203-1213.

PMID: 37532945 PMC: 10471675. DOI: 10.1007/s00270-023-03520-z.


Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey.

Wunsch E, Krause L, Gevers T, Schramm C, Janik M, Krawczyk M Liver Int. 2022; 43(2):381-392.

PMID: 36177700 PMC: 10091761. DOI: 10.1111/liv.15440.


Incidence, Impact and Treatment of Ongoing CMV Infection in Patients with Biliary Atresia in Four European Centres.

Fischler B, Czubkowski P, Dezsofi A, Liliemark U, Socha P, Sokol R J Clin Med. 2022; 11(4).

PMID: 35207217 PMC: 8879500. DOI: 10.3390/jcm11040945.


Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.

Cortez-Pinto H, Liberal R, Lopes S, Machado M, Carvalho J, Dias T United European Gastroenterol J. 2021; 9(6):699-706.

PMID: 34102008 PMC: 8280809. DOI: 10.1002/ueg2.12095.


Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy.

Carbone M, Kodra Y, Rocchetti A, Manno V, Minelli G, Gerussi A Int J Environ Res Public Health. 2020; 17(9).

PMID: 32365682 PMC: 7246900. DOI: 10.3390/ijerph17093095.

References
1.
. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017; 67(1):145-172. DOI: 10.1016/j.jhep.2017.03.022. View

2.
Lee J, Danford C, Trivedi H, Tapper E, Patwardhan V, Bonder A . Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2019; 64(8):2338-2350. DOI: 10.1007/s10620-019-5457-5. View

3.
van Grinsven J, van Brunschot S, van Santvoort H . The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis. Gastroenterology. 2017; 152(4):685-688.e6. DOI: 10.1053/j.gastro.2017.01.040. View

4.
Trauner M, Nevens F, Shiffman M, Drenth J, Bowlus C, Vargas V . Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019; 4(6):445-453. DOI: 10.1016/S2468-1253(19)30094-9. View

5.
Wobser H, Paur T, Schnoy E, Hartl J, Kirchner G . Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. United European Gastroenterol J. 2018; 6(2):247-254. PMC: 5833219. DOI: 10.1177/2050640617711632. View